GHK-Cu Research Profile: Copper Peptide Studies on Skin Repair, Hair Growth, and Aging

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide first isolated from human plasma in the 1970s by biochemist Loren Pickart. It has since become one of the most studied peptides in dermatological and wound healing research. GHK-Cu is naturally present in human plasma, saliva, and urine, with plasma concentrations reported to decline with age. This profile from the Peptide Register summarises what the published literature reports, with attention to study quality and the significant gaps that remain.

What Is GHK-Cu and How Does It Work?

GHK-Cu is a tripeptide composed of three amino acids (glycine, histidine, lysine) with a strong binding affinity for copper(II) ions. As a small peptide, it falls within the broader category of bioactive signalling peptides rather than structural proteins like collagen.

The proposed mechanism of action centres on copper delivery and gene expression modulation. GHK-Cu has a molecular weight of approximately 403 daltons, making it small enough for topical absorption. In vitro studies suggest that GHK-Cu modulates the expression of multiple genes involved in tissue remodelling, antioxidant defence, and inflammation. A widely cited 2012 gene expression study by Pickart and colleagues reported that GHK-Cu may influence the activity of over 4,000 human genes, with patterns suggesting a shift toward younger gene expression profiles. However, this was a bioinformatics analysis using the Broad Institute's Connectivity Map, not a direct experimental confirmation in living tissue, and this distinction is important when evaluating the strength of the evidence.

Skin Repair and Wound Healing Evidence

GHK-Cu has been studied in wound healing contexts since the 1980s. In animal models, GHK-Cu has been reported to stimulate collagen synthesis, promote angiogenesis, and accelerate wound closure. Several in vitro studies have shown that GHK-Cu increases collagen types I and III production in fibroblast cultures and upregulates decorin expression.

A small number of human studies have examined topical GHK-Cu formulations. In one controlled trial involving 71 participants, a topical cream containing GHK-Cu was reported to improve skin laxity and reduce fine lines over a 12-week period compared to placebo and vitamin C controls. While these results are suggestive, the trial was modest in scale and industry-funded, warranting cautious interpretation. Researchers interested in related wound healing peptides may also find our coverage of Thymosin Beta-4 relevant for comparison.

GHK-Cu has been reported to increase dermal fibroblast proliferation and glycosaminoglycan synthesis in cell culture studies. These findings are consistent across multiple in vitro experiments but have not been replicated at the same scale in human clinical trials.

Hair Growth Research

GHK-Cu has attracted interest in hair loss research, though the evidence base here is notably thinner than for skin. In vitro studies suggest that GHK-Cu may stimulate hair follicle growth by increasing follicle size and prolonging the anagen (growth) phase. One study on isolated human hair follicles reported increased proliferation of dermal papilla cells when exposed to GHK-Cu.

GHK-Cu has been investigated as a potential hair growth agent, but no large-scale randomised controlled trials in humans have been published as of 2025. Most hair-related findings come from cell culture or small observational studies, and the translation from in vitro follicle stimulation to clinically meaningful hair regrowth remains unconfirmed. This is an area where the gap between preliminary findings and clinical validation is especially wide, a pattern common across peptide research as discussed in our guide on how to read peptide research.

Regulatory Status and Safety Considerations

GHK-Cu is not approved by the FDA or TGA as a therapeutic drug. In cosmetic formulations, GHK-Cu appears in various over-the-counter skincare products, where it is classified as a cosmetic ingredient rather than a drug. GHK-Cu is not FDA-approved as a therapeutic drug and is primarily available as a cosmetic ingredient in topical skincare formulations.

In Australia, peptide regulation is complex and evolving. GHK-Cu's regulatory classification depends on the formulation and intended use. Injectable forms of peptides generally fall under stricter scheduling requirements; readers can explore our peptide regulation overview for jurisdiction-specific details.

Reported side effects in topical studies have generally been mild, including localised irritation. However, long-term safety data for GHK-Cu remain limited, particularly for non-topical routes of administration. The copper component raises theoretical concerns about copper accumulation at high doses, though this has not been systematically studied in clinical settings.

Key Limitations and Open Questions

GHK-Cu plasma concentrations have been reported to decline from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60. This age-related decline is frequently cited as a rationale for supplementation research, though causation between declining GHK-Cu levels and specific aging outcomes has not been established.

Much of the GHK-Cu evidence base relies on in vitro cell culture and animal models rather than large human clinical trials. The gene expression modulation data, while extensive, comes primarily from bioinformatics analyses rather than direct experimental measurement in human tissue. Replication of key findings by independent research groups remains limited.

The Peptide Register maintains a detailed peptide database cataloguing the current evidence for GHK-Cu and other peptides under active investigation. As always, this content is intended as an educational reference, not as medical advice or an endorsement of any product or protocol.